Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. - Wikidata - wikimedia - TriplyDB

Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.

Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.

http://www.wikidata.org/entity/Q36908288

about

Recurrence and Treatment after Renal Transplantation in Children with FSGS Update on the treatment of focal segmental glomerulosclerosis in renal transplantation FSGS Recurrence in Adults after Renal Transplantation Immunologic Changes Implicated in the Pathogenesis of Focal Segmental Glomerulosclerosis Plasma Exchange for the Recurrence of Primary Focal Segmental Glomerulosclerosis in Adult Renal Transplant Recipients: A Meta-Analysis Recent advances in the understanding of immune-mediated nephrotic syndrome: diagnostic and prognostic implications.Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?Developing therapeutic 'arrows' with the precision of William Tell: the time has come for targeted therapies in kidney disease.CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease.Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients.Abatacept for the treatment of systemic lupus erythematosus.Focal segmental glomerular sclerosis: do not overlook the role of immune response.Targeting the podocyte cytoskeleton: from pathogenesis to therapy in proteinuric kidney disease.Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms.Minimal change disease and idiopathic FSGS: manifestations of the same disease.Steroid-resistant nephrotic syndrome: a persistent challenge for pediatric nephrology.Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome.Successful Treatment of Focal Segmental Glomerulosclerosis after Kidney Transplantation with Plasma Exchange and Abatacept in a Patient with Juvenile Rheumatoid Arthritis.Costimulatory blockade: A novel approach to the treatment of glomerular disease?Unsuccessful Treatment with Abatacept in Recurrent Focal Segmental Glomerulosclerosis after Kidney Transplantation.Recurrence of primary glomerulonephritis: Review of the current evidence.Recurrence of primary glomerulonephritis: Review of the current evidence.Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome.Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?Actin dynamics at focal adhesions: a common endpoint and putative therapeutic target for proteinuric kidney diseases.Urinary CD80: a biomarker for a favorable response to corticosteroids in minimal change disease.B7-1 biomarker bites the dust.Remaining Physiological Barriers in Porcine Kidney Xenotransplantation: Potential Pathways behind Proteinuria as well as Factors Related to Growth Discrepancies following Pig-to-Kidney Xenotransplantation.CD80 and CTLA-4 as diagnostic and prognostic markers in adult-onset minimal change disease: a retrospective study

P2860

Q26746985-ACCE23A4-B408-4AC5-B9A3-88A46FB873EE Q26751470-976EFD2A-ADBE-4992-82BF-9C92A7E7B4CA Q26752840-A9B83555-ACF9-4DAE-A05E-870D9B4A2A0D Q26753833-C1AA1B70-C4A5-4540-9DF0-36B009663C77 Q26772265-DF0CB974-9A32-4CED-AF02-69CE50BAF623 Q38371343-9A9C70D4-1EA2-487B-AEA4-C8647243D69E Q38458152-173C84A4-E887-4BF5-B26F-1B89245AE909 Q38518588-E2412207-3936-499A-80AF-3E161902B7C6 Q38593433-99A2C56D-DE24-471C-8AFC-AAE1E911D694 Q38675622-3F3729DB-D763-49F0-B79A-6E1CCCBA4594 Q38734009-EE4C1804-A2A5-42C1-8185-89A8946FCFB1 Q38742004-253263D2-54EE-49B0-B6FB-E3C36C235000 Q38770231-740BCF5F-4586-4943-8361-0799C45D2AA6 Q38844709-DBACDD04-31C4-4956-ADFB-AE715395A214 Q38982416-4F62BE85-45E4-4C1B-A2F7-6C0BF16EAB39 Q38991259-437167B7-C19B-477B-881B-0288A0F6FC24 Q39335899-F21F6354-43FC-4C4A-8A6D-4A2A45EF1A85 Q39815667-B79498C4-0F29-4486-A795-7BC0E159452D Q40771026-C0383F7D-5491-4063-98D8-EBBA0CE340C7 Q42322601-37B3B03C-535B-4638-81FA-F49117C7EC93 Q47193282-4500D26B-4DDD-4415-BEBB-61AE6BECB74E Q47243136-088A8787-E1AE-4999-A399-4DA4592B3951 Q49772713-064112F5-02AB-43E9-BA22-494ED79BFBA9 Q50856119-A01D1ADB-FC3A-4F63-A9E5-A93514D7E2C7 Q52573827-CD581902-F2C7-4F2D-82C1-C7C03527161D Q52729712-30493083-FEF1-4157-98A6-B2116E73D7F0 Q53846817-4A69F4F0-5AEB-4D05-BB1C-2A1C4386FBC9 Q55240040-5AC12028-B98E-4BEF-A9F7-4D98E68D7F72 Q56890381-570514CF-596E-4CAE-A9C8-B94936283757

P2860

Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.

http://www.wikidata.org/entity/Q36908288

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Case series: CTLA4-IgG1 therap ...... segmental glomerulosclerosis.

@en

type

label

Case series: CTLA4-IgG1 therap ...... segmental glomerulosclerosis.

@en

prefLabel

Case series: CTLA4-IgG1 therap ...... segmental glomerulosclerosis.

@en

P1433

Q36908288-68FF69B5-51EC-4C4C-8201-1646766D6F3D

P1476

Q36908288-38AEC457-1B4C-4E92-AC2A-04371AA152FC

P2093

Q36908288-12E00B27-8FA8-4F1E-BB9B-551CBB4A95D8

Q36908288-34465A29-9102-41C3-BB49-3B621720F8F3

Q36908288-773C3EE2-DCBA-4263-B7F5-8DE946A99434

Q36908288-9E8845F3-A10E-4D63-9119-48FAD47E4F69

Q36908288-A5482AC0-49EE-455D-9533-478A37AD7211

Q36908288-B4B49F0C-059A-4D73-ABF3-6BC64A77A84C

Q36908288-FF2CD958-72A3-4329-B5C2-AFAA8B735D8D

P2860

Q36908288-158401A8-19FF-42DA-A292-28FCDBC08B67

Q36908288-19799902-A9AD-4C9F-B0F3-87E2F183CC4D

Q36908288-2AC513EC-319F-4238-8439-F36964261602

Q36908288-2BD5B59C-EF3A-4B73-9065-7A4E39A18722

Q36908288-30F8E313-6DD5-4E22-9CE3-F48373627E8B

Q36908288-3B37FCB7-ADB5-400F-BB5F-FCD0F4D4F444

Q36908288-3BF91550-4E2F-4597-A6B9-F1A94D36745A

Q36908288-499442DC-0139-4AA6-9C0E-E3ED39704BE1

Q36908288-4A385F93-4D85-4DCA-B2EC-4FE1839B158D

Q36908288-67E8803C-E9F2-45B6-BBE3-D44579871357

P2888

Q36908288-969CBC6C-EFAE-4243-B623-F1DCFE32DF48

P304

Q36908288-E02A5E14-FAC7-46CC-B334-057A16D7145E

P31

Q36908288-06551D5F-89BB-4FFB-A420-EAC37F3390B1

P356

Q36908288-3B3B64A2-B4E7-456B-968C-F3D80A126878

P433

Q36908288-51DDB211-D319-4D57-AB61-AEABAF5ADE32

P478

Q36908288-97F6E509-28B7-4D4F-81EB-17819BC7D190

P50

Q36908288-68E1FAA0-A122-4B1B-BAAF-6E6F065078CB

P577

Q36908288-A6CA8FC2-8BE4-4B78-9BAD-79094C183ED2

P698

Q36908288-C7776D24-0D16-42F7-9E8B-B089D3D62E8D

P932

Q36908288-1630A353-C9B8-4CC7-8D65-74433C99B883

P356

S00467-014-2957-6

P1433

Pediatric Nephrology

P1476

Case series: CTLA4-IgG1 therap ...... segmental glomerulosclerosis.

@en

P2093

Changli Wei

http://www.w3.org/2001/XMLSchema#string

Dany Matar

http://www.w3.org/2001/XMLSchema#string

Eduardo H Garin

http://www.w3.org/2001/XMLSchema#string

Gabriel Cara-Fuentes

http://www.w3.org/2001/XMLSchema#string

Heiman Wang

http://www.w3.org/2001/XMLSchema#string

Jochen Reiser

http://www.w3.org/2001/XMLSchema#string

Richard J Johnson

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of adenosine 2A receptors preserves structure and function of podocytes

Induction of B7-1 in podocytes is associated with nephrotic syndrome

Role of podocyte B7-1 in diabetic nephropathy

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.

Minimal change disease: a dysregulation of the podocyte CD80-CTLA-4 axis?

Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice.

CTLA-4 is a second receptor for the B cell activation antigen B7

Circulating suPAR in two cohorts of primary FSGS.

A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases.

Urinary CD80 excretion increases in idiopathic minimal-change disease

P2888

s00467-014-2957-6

P304

469-477

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00467-014-2957-6

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25239302

http://www.w3.org/2001/XMLSchema#string

P932

4869736

http://www.w3.org/2001/XMLSchema#string